In this study, we demonstrated for the first time that KS-133, a VIPR2-selective antagonistic peptide, increases M1-type macrophage markers and decreases M2-type macrophage markers in vitro, exhibits anti-tumor efficacy in vivo, and enhances the pharmacological efficacy of an anti-PD-1 antibody. Here, VIPR2 is linked to neoplasm.